Hola,
Are you new here?

GNA NOW

financed

NOVEL GRAM NEGATIVE ANTIBIOTIC NOW

AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to addr... see more

31/12/2025

FOUNDATION LYGATUR...

22M€

Project Budget: 22M€

Project leader

STICHTING LYGATURE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 13 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2019-06-17

IMI2-2018-16-07: Intravenous treatments of serious i... Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator pro...

I+D

Cerrada does 6 years

0% 57% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

FOUNDATION LYGATURE

757.56K€ | Leader

GLAXOSMITHKLINE INVESTIGACIO...

570.00K€ | participant

ERASMUS MC

1.20M€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 78 months Date Start: 2019-06-17
End date: 2025-12-31

Project leader

STICHTING LYGATURE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 22M€

participation deadline Sin fecha límite de participación.

Project description AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics. Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers